Search

Displaying results 2251 - 2260 of 10000 in total
  1. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors … Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency.

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  2. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

  3. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    [L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. … Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.

  4. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    This drug was developed by Chiasma Inc.[L14495,L14507,L14528] … [L14513] In the past, octreotide has been administered solely by injection.

  5. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic

  6. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]

  7. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

  8. Drug

    Pomalidomide

    go.drugbank.com/drugs/DB08910
    ApprovedInvestigational

    Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

  9. Drug

    Ibuproxam

    go.drugbank.com/drugs/DB08955
    ApprovedWithdrawn

    Ibuproxam is a non steroidal anti-inflammatory drug (NSAID).

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  10. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]